Oxaliplatin/5-fluorouracil in advanced hepatocellular carcinoma: Case report and single-center retrospective review

Future Oncology

Volumn 10, Issue 13, 2014, Pages 2007-2014

  Goldstein, Robert ^a,b   Yu, Dominic ^a   Gillmore, Roopinder ^a,b   Thirlwell, Christina ^a,b   O'Donoghue, Pam ^b   Mayer, Astrid ^a,b   Meyer, Tim ^a,b  

^a UNIVERSITY COLLEGE LONDON   (United Kingdom)

^b ROYAL FREE HOSPITAL   (United Kingdom)

Author keywords

FOLFOX; Hepatocellular carcinoma; Liver transplantation; Sorafenib

Indexed keywords

ALPHA FETOPROTEIN; DOXORUBICIN; FLUOROURACIL; FOLINIC ACID; OXALIPLATIN; PROTEIN TYROSINE KINASE INHIBITOR; SORAFENIB; ANTINEOPLASTIC AGENT; PLATINUM COMPLEX;

ADVANCED CANCER; AGED; ARTICLE; CANCER COMBINATION CHEMOTHERAPY; CANCER DIAGNOSIS; CANCER GRADING; CANCER RECURRENCE; CANCER SURGERY; CANCER SURVIVAL; CHEMOTHERAPY INDUCED ANEMIA; CLINICAL ARTICLE; CONTRAST ENHANCEMENT; CONTROLLED STUDY; DRUG DOSE INCREASE; DRUG EFFICACY; DRUG SAFETY; FOLLOW UP; HUMAN; LEUKOPENIA; LIVER CELL CARCINOMA; LIVER FUNCTION; LYMPHOCYTOPENIA; MALE; NEUTROPENIA; NEUTROPENIC SEPSIS; NON INVASIVE MEASUREMENT; NUCLEAR MAGNETIC RESONANCE IMAGING; OVERALL SURVIVAL; RADIOFREQUENCY ABLATION; RETROSPECTIVE STUDY; SEPSIS; THROMBOCYTOPENIA; TREATMENT DURATION; TREATMENT RESPONSE; ADVERSE EFFECTS; ARTIFICIAL EMBOLISM; CANCER STAGING; CARCINOMA, HEPATOCELLULAR; CASE REPORT; CHILD; LIVER NEOPLASMS; PATHOLOGY; PROCEDURES; TREATMENT OUTCOME;

ANTINEOPLASTIC COMBINED CHEMOTHERAPY PROTOCOLS; CARCINOMA, HEPATOCELLULAR; CHILD; EMBOLIZATION, THERAPEUTIC; FLUOROURACIL; HUMANS; LIVER NEOPLASMS; MALE; NEOPLASM STAGING; ORGANOPLATINUM COMPOUNDS; RETROSPECTIVE STUDIES; TREATMENT OUTCOME;

EID: 84911164273     PISSN: 14796694     EISSN: 17448301     Source Type: Journal    
DOI: 10.2217/FON.14.108     Document Type: Article

References (20)

1. Jemal A, Bray F, Center MM, Ferlay J, Ward E, Forman D. Global cancer statistics. CA Cancer J. Clin. 61(2), 69-90 (2011).
2. Parkin DM. The global health burden of infection-associated cancers in the year 2002. Int. J. Cancer 118(12), 3030-3044 (2006).
3. Cheng AL, Kang YK, Chen Z et al. Efficacy and safety of sorafenib in patients in the Asia-Pacific region with advanced hepatocellular carcinoma: a Phase III randomized, double-blind, placebo-controlled trial. Lancet Oncol. 10(1), 25-34 (2009).
4. Llovet JM, Ricci S, Mazzaferro V et al. Sorafenib in advanced hepatocellular carcinoma. N. Engl. J. Med. 359(4), 378-390 (2008).
5. Asghar U, Meyer T. Are there opportunities for chemotherapy in the treatment of hepatocellular cancer? J. Hepatol. 56(3), 686-695 (2012).
6. Qin S, Bai Y, Lim HY et al. Randomized, multicenter, open-label study of oxaliplatin plus fluorouracil/leucovorin versus doxorubicin as palliative chemotherapy in patients with advanced hepatocellular carcinoma from Asia. J. Clin. Oncol. 31(28), 3501-3508 (2013).
7. Lai CL, Wu PC, Chan GC, Lok AS, Lin HJ. Doxorubicin versus no antitumor therapy in inoperable hepatocellular carcinoma. A prospective randomized trial. Cancer 62(3), 479-483 (1988).
8. European Association for the Study of the Liver, European Association for the Study of the Liver. EASL-EORTC clinical practice guidelines: management of hepatocellular carcinoma. J. Hepatol. 56(4), 908-943 (2012).
9. Burroughs A, Hochhauser D, Meyer T. Systemic treatment and liver transplantation for hepatocellular carcinoma: two ends of the therapeutic spectrum. Lancet Oncol. 5(7), 409-418 (2004).
10. Abou-Alfa GK, Johnson P, Knox JJ et al. Doxorubicin plus sorafenib vs doxorubicin alone in patients with advanced hepatocellular carcinoma: a randomized trial. JAMA 304, 2154-2160 (2010).
11. Tan-Shalaby J. Complete radiographic remission with 5-fluorouracil and leucovorin after sorafenib failure in hepatocellular carcinoma: Is there a role for chemotherapy after targeted agents? BMJ Case Rep. doi:10.1136bcr-2013-010362 (2013) (Epub ahead of print).
12. Boige V, Raoul JL, Pignon JP et al. Multicenter Phase II trial of capecitabine plus oxaliplatin (XELOX) in patients with advanced hepatocellular carcinoma: FFCD 03-03 trial. Br. J. Cancer 97(7), 862-867 (2007).
13. He SL, Shen J, Sun XJ, Zhu XJ, Liu LM, Dong JC. Efficacy of capecitabine and oxaliplatin regimen for extrahepatic metastasis of hepatocellular carcinoma following local treatments. World J. Gastroenterol. 19(28), 4552-4558 (2013).
14. Coriat R, Mir O, Cessot A et al. Feasibility of oxaliplatin, 5-fluorouracil and leucovorin (FOLFOX-4) in cirrhotic or liver transplant patients: experience in a cohort of advanced hepatocellular carcinoma patients. Invest. New Drugs 30(1), 376-381 (2012).
15. Johnson PJ, Qin S, Park JW et al. Brivanib versus sorafenib as first-line therapy in patients with unresectable, advanced hepatocellular carcinoma: results from the randomized Phase III BRISK-FL study. J. Clin. Oncol. 31(28), 3517-3524 (2013).
16. Cheng AL, Kang YK, Lin DY et al. Sunitinib versus sorafenib in advanced hepatocellular cancer: results of a randomized Phase III trial. J. Clin. Oncol. 31(32), 4067-4075 (2013).
17. Llovet JM, Decaens T, Raoul JL et al. Brivanib in patients with advanced hepatocellular carcinoma who were intolerant to sorafenib or for whom sorafenib failed: results from the randomized Phase III BRISK-PS study. J. Clin. Oncol. 31(28), 3509-3516 (2013).
18. Sposito C, Mariani L, Germini A et al. Comparative efficacy of sorafenib versus best supportive care in recurrent hepatocellular carcinoma after liver transplantation: a case-control study. J. Hepatol. 59(1), 59-66 (2013).
19. Staufer K, Fischer L, Seegers B, Vettorazzi E, Nashan B, Sterneck M. High toxicity of sorafenib for recurrent hepatocellular carcinoma after liver transplantation. Transpl. Int. 25(11), 1158-1164 (2012).
20. Gomez-Martin C, Bustamante J, Castroagudin JF et al. Efficacy and safety of sorafenib in combination with mammalian target of rapamycin inhibitors for recurrent hepatocellular carcinoma after liver transplantation. Liver Transpl. 18(1), 45-52 (2012).